for the 0, 300, and 600 mg/day sdg groups, respectively, the international prostate symptom score (ipss) decreased -3.67 +/- 1.56, -7.33 +/- 1.18, and -6.88 +/- 1.43 (mean +/- se, p = .100, < .001, and < .001 compared to baseline), the quality of life score (qol score) improved by -0.71 +/- 0.23, -1.48 +/- 0.24, and -1.75 +/- 0.25 (mean +/- se, p = .163 and .012 compared to placebo and p = .103, < .001, and < .001 compared to baseline), and the number of subjects whose luts grade changed from "moderate/severe" to "mild" increased by three, six, and 10 (p = .188, .032, and .012 compared to baseline).